NZ503007A - Conjugates that contain the homeodomain of antennapedia - Google Patents

Conjugates that contain the homeodomain of antennapedia

Info

Publication number
NZ503007A
NZ503007A NZ503007A NZ50300798A NZ503007A NZ 503007 A NZ503007 A NZ 503007A NZ 503007 A NZ503007 A NZ 503007A NZ 50300798 A NZ50300798 A NZ 50300798A NZ 503007 A NZ503007 A NZ 503007A
Authority
NZ
New Zealand
Prior art keywords
antennapedia
homeodomain
conjugates
contain
region
Prior art date
Application number
NZ503007A
Other languages
English (en)
Inventor
Andrea Crisanti
Original Assignee
Imp College Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp College Innovations Ltd filed Critical Imp College Innovations Ltd
Publication of NZ503007A publication Critical patent/NZ503007A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Insects & Arthropods (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Variable-Direction Aerials And Aerial Arrays (AREA)
  • Medicinal Preparation (AREA)
NZ503007A 1997-09-02 1998-09-02 Conjugates that contain the homeodomain of antennapedia NZ503007A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9718609.2A GB9718609D0 (en) 1997-09-02 1997-09-02 Fusion protein
PCT/GB1998/002628 WO1999011809A1 (en) 1997-09-02 1998-09-02 Conjugates that contain the homeodomain of antennapedia

Publications (1)

Publication Number Publication Date
NZ503007A true NZ503007A (en) 2000-11-24

Family

ID=10818419

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ503007A NZ503007A (en) 1997-09-02 1998-09-02 Conjugates that contain the homeodomain of antennapedia

Country Status (10)

Country Link
US (2) US7968512B2 (https=)
EP (1) EP1009847A1 (https=)
JP (1) JP2001514858A (https=)
AU (1) AU737829B2 (https=)
BR (1) BR9811744A (https=)
CA (1) CA2301157A1 (https=)
GB (1) GB9718609D0 (https=)
IL (2) IL134602A0 (https=)
NZ (1) NZ503007A (https=)
WO (1) WO1999011809A1 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001505055A (ja) * 1996-12-02 2001-04-17 ウエイク・フオレスト・ユニバーシテイ Hiv感染の治療としてのhivコレセプターの不活性化
CA2314267A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
DK1129064T3 (da) 1998-11-12 2008-04-28 Invitrogen Corp Transfektionsreagenser
IL142869A0 (en) 1998-11-13 2002-03-10 Cyclacel Ltd Transport vectors
AU762006B2 (en) 1998-12-24 2003-06-19 Ucb Peptidic product, process and composition
WO2000058488A2 (en) * 1999-03-31 2000-10-05 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
US6773920B1 (en) 1999-03-31 2004-08-10 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
US6372494B1 (en) 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
EP1118668A1 (en) * 2000-01-07 2001-07-25 ARTEMIS Pharmaceuticals GmbH Transduction of recombinases for inducible gene targeting
EP1244796A2 (en) * 2000-01-07 2002-10-02 ARTEMIS Pharmaceuticals GmbH Transduction of recombinases for inducible gene targeting
GB0003284D0 (en) * 2000-02-15 2000-04-05 Secr Defence Brit Anti-viral therapy
US20040110928A1 (en) * 2000-04-12 2004-06-10 Andrea Crisanti Peptide conjugates for drug delivery
DE10027777A1 (de) * 2000-06-07 2001-12-13 Otogene Ag Transfektionsverfahren
GB0015090D0 (en) * 2000-06-20 2000-08-09 Implyx Ltd Gene-activating conjugates
KR100374050B1 (ko) * 2000-07-26 2003-03-03 최수영 세포침투성 융합단백질, 이를 코딩하는 재조합폴리뉴클레오타이드 및 발현벡터
US20030027335A1 (en) * 2000-09-07 2003-02-06 Ruley H. Earl Genome engineering by cell-permeable DNA site-specific recombinases
US6472176B2 (en) * 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
CA2367636C (en) 2001-04-12 2010-05-04 Lisa Mckerracher Fusion proteins
US7442686B2 (en) 2001-04-12 2008-10-28 Bioaxone Therapeutique Inc. Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
EP1406573A4 (en) * 2001-06-07 2005-03-30 Skinmedica Inc CONDITIONED CELL CULTURE MEDIA AND ITS USES
GB0124391D0 (en) * 2001-10-11 2001-11-28 Gene Expression Technologies L Control of gene expression
US20050136040A1 (en) * 2001-10-11 2005-06-23 Imperial College Innovations Limited Control of gene expression using a complex of an oligonucleotide and a regulatory peptide
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
DE102007041655A1 (de) 2007-09-03 2009-03-05 Medicyte Gmbh Vermehrung von primären Zellen und deren Verwendung
US8119366B2 (en) 2007-10-05 2012-02-21 Trojan Technologies, Ltd. Antennapedia-dominant negative mastermind-like construct
AU2010238346A1 (en) 2009-04-14 2011-11-03 Trojan Technologies Ltd. Therapeutic Antennapedia-antibody molecules and methods of use thereof
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
DE102010041958A1 (de) 2010-10-04 2012-04-05 Medicyte Gmbh Geeignete Hepatozyten für in-vitro Genotoxitätstests
US20140296154A1 (en) * 2011-05-06 2014-10-02 Yale University Method of preventing development of psoriatic lesions
ES2633343T3 (es) * 2011-06-13 2017-09-20 The Board Of Trustees Of The University Of Illionis Composiciones de péptidos y métodos para tratar lesión pulmonar, asma, anafilaxis, angioedema, síndromes de permeabilidad vascular sistémica y congestión nasal
US9937242B2 (en) 2012-04-09 2018-04-10 Case Western Reserve University Compositions and methods for inhibiting the activity of LAR family phosphatases
WO2013184527A1 (en) 2012-06-05 2013-12-12 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
AU2013302799B2 (en) 2012-08-13 2018-03-01 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
CA2915296A1 (en) * 2013-06-11 2015-02-26 Portage Pharmaceuticals Ltd. Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides
EP2927685A1 (en) 2014-04-02 2015-10-07 Medicyte GmbH Suitable hepatocytes for in-vitro hepatitis tests
WO2016011203A1 (en) 2014-07-15 2016-01-21 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
CA2962444C (en) 2014-10-03 2023-09-05 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
BR112017018665A2 (pt) 2015-03-02 2018-04-24 The Board Of Trustees Of The University Of Illinois peptídeos para inibição de angiogênese
EP3402543B1 (en) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
JP2019513752A (ja) 2016-04-07 2019-05-30 ケース ウエスタン リザーブ ユニバーシティ 神経変性疾患を治療するためのtdp−43のミトコンドリア局在化阻害剤
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
US11541078B2 (en) 2016-09-20 2023-01-03 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
EP4699658A2 (en) 2017-04-19 2026-02-25 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
CN111093684A (zh) 2017-07-11 2020-05-01 凯斯西储大学 用于治疗髓鞘病症的组合物和方法
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
US12146137B2 (en) 2018-02-05 2024-11-19 Cedars-Sinai Medical Center Methods for therapeutic use of exosomes and Y-RNAS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2739621B1 (fr) * 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives

Also Published As

Publication number Publication date
US8735340B2 (en) 2014-05-27
US20080317773A1 (en) 2008-12-25
GB9718609D0 (en) 1997-11-05
WO1999011809A1 (en) 1999-03-11
BR9811744A (pt) 2002-01-02
EP1009847A1 (en) 2000-06-21
AU8877698A (en) 1999-03-22
CA2301157A1 (en) 1999-03-11
AU737829B2 (en) 2001-08-30
US20110256168A1 (en) 2011-10-20
JP2001514858A (ja) 2001-09-18
IL134602A0 (en) 2001-04-30
US7968512B2 (en) 2011-06-28
IL134602A (en) 2006-10-31

Similar Documents

Publication Publication Date Title
NZ503007A (en) Conjugates that contain the homeodomain of antennapedia
PL347932A1 (en) Interferon-beta fusion proteins and uses
ZA9810679B (en) Antimicrobial peptides.
WO1998040401A3 (en) Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
NZ503850A (en) April - a novel protein with growth effects
WO1995013297A3 (en) Improved immunogenic compositions against human gastrin 17
ZA9811593B (en) Substantially pure histidine-linked protein polymer conjugates
IL125124A0 (en) Dimeric forms of the protein fapalpha and uses thereof
ZA986358B (en) Dolastatin 15 derivatives.
AU3843897A (en) Self-aligning peptides derived from elastin and other fibrous proteins
GB9705903D0 (en) VP22 Proteins and uses thereof
EP0644884A4 (en) NOVEL TETRAHYDROCANNABINOL DERIVATIVES, CONJUGATES AND TRACERS OF TETRAHYDROCANNABINOL DERIVATIVES FIXED TO PROTEINS AND POLYPEPTIDES.
ZA977511B (en) Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides.
GR3031122T3 (en) Stable lyophilized thiotepa composition.
ZA964825B (en) Collagen peptide fraction and its uses.
ZA98642B (en) Immune-modulation with amino acids
ZA9410217B (en) Recombinant human thymopoietin proteins and uses therefor.
EP1431391A3 (en) Rantes mutants and therapeutic applications thereof
AU2004595A (en) Process for preparing recombinant aprotinin and recombinant aprotinin variants having the natural N-terminal sequence
GB2336844B (en) Anti-hiv peptides and proteins
EP0935608A4 (en) CYTOTOXIC PEPTIDES
ZA988070B (en) Insulin-like polypeptide and uses therefor.
CA2247998A1 (en) Fragments of cr1 and their use
ZA987206B (en) Cycline-dependent protein kinase-activating kinase and its uses
AU2826197A (en) Bovine dipeptidylaminopeptidase 1

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: TROJAN TECHNOLOGIES LIMITED, GB

Free format text: OLD OWNER(S): IMPERIAL COLLEGE INNOVATIONS LIMITED

EXPY Patent expired